Comparing the risk of hepatitis B virus reactivation between direct‐acting antiviral therapies and interferon‐based therapies for hepatitis C
暂无分享,去创建一个
N. Sakamoto | M. Natsuizaka | T. Sho | N. Kawagishi | G. Suda | M. Kimura | O. Maehara | M. Ohara | M. Nakai | M. Onozawa | M. Umemura | T. Izumi | K. Ogawa | K. Morikawa | J. Ito